ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Health Technology

Ono Pharmaceutical Co., Ltd.

  • 2,030.50 JPY
  • -8.50
  • -0.42%
  • Japan
    Apr 23, 2019
  • Ticker
    TKS(4528)
  • Prev. close
    2,039
  • Market cap (JPY)
    1,107.87B
  • Market cap (USD)
    9,898.35M
  • Shares
    543.34M

Business Summary

Ono Pharmaceutical Co., Ltd. engages in the production, purchase, and sale of internal medicine, patch and injectable medicine. The company was founded by Ichibei Fushimiya in 1717 and is headquartered in Osaka, Japan.

Financial Highlights

Mar 2018 JPYUSD
Revenue261,836M2,362.44M
Gross Profit194,743M1,757.09M
Operating income59,569M537.46M
Income before tax63,922M576.74M
Net income50,284M453.69M
EBITDA68,782M620.59M
Diluted EPS96.990.87
Dividends Per Share450.40
Total Assets609,226M5,728.49M
Total liabilities79,012.59M742.94M
Total equity524,390M4,930.79M
Operating cash flow15,727M141.89M
Currency in JPYCurrency in USD

Historical Data

 Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018
Revenue 143,247M 135,775M 160,284M 244,797M 261,836M
Gross Profit 109,020M 99,241M 117,409M 177,884M 194,743M
Operating income 26,265M 15,355M 30,014M 59,718M 59,569M
Income before tax 29,460M 18,292M 33,304M 74,540M 63,922M
Net income 20,344M 12,976M 24,979M 55,793M 50,284M
EBITDA 31,374M 21,455M 36,548M 67,539M 68,782M
Diluted EPS 38.38 24.48 47.13 105.26 96.99
Dividends Per Share 36 36 36 40 45
Total Assets 486,141M 524,588M 540,450M 617,461M 609,226M
Total liabilities 34,417M 49,375M 64,195M 92,118M 79,012.59M
Total equity 447,327M 470,575M 471,393M 519,110M 524,390M
Operating cash flow 28,422M 31,579M 12,842M 74,450M 15,727M
 Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018
Revenue 1,430.01M 1,235.93M 1,334.76M 2,260.62M 2,362.44M
Gross Profit 1,088.33M 903.36M 977.72M 1,642.70M 1,757.09M
Operating income 262.20M 139.77M 249.94M 551.47M 537.46M
Income before tax 294.09M 166.50M 277.33M 688.35M 576.74M
Net income 203.09M 118.11M 208.01M 515.23M 453.69M
EBITDA 313.20M 195.30M 304.35M 623.70M 620.59M
Diluted EPS 0.38 0.22 0.39 0.97 0.87
Dividends Per Share 0.35 0.32 0.29 0.36 0.40
Total Assets 4,720.50M 4,374.30M 4,808.48M 5,541.24M 5,728.49M
Total liabilities 334.19M 411.71M 571.15M 826.68M 742.94M
Total equity 4,343.61M 3,923.91M 4,194.07M 4,658.61M 4,930.79M
Operating cash flow 283.73M 287.45M 106.94M 687.52M 141.89M

Valuation Measures

Mar 2018
PER33.95
ROA8.19%
ROE9.63%
Operating margin22.75%
Profit margin19.20%

Key executives

  • President & Representative Director: Gyo Sagara
  • Director & Executive Vice President: Hiroshi Awata
  • Executive Officer & Manager-NV Strategy Planning: Shozo Matsuoka
  • Executive Officer & GM-Business Strategy: Toichi Takino
  • Director & GM-Business Administration: Kei Sano

Shareholders

  • Wellington Management Co. LLP (6.8%)
  • Ono Pharmaceutical Co., Ltd. (5.3%)
  • Meiji Yasuda Life Insurance Co. (3.4%)
  • Ono Shogakukai Foundation (3.0%)
  • Kakumeiso Co. Ltd. (2.9%)
  • The Vanguard Group, Inc. (2.0%)
  • Nomura Asset Management Co., Ltd. (1.7%)
  • Mitsubishi UFJ Financial Group, Inc. (1.5%)
  • MS&AD Insurance Group Holdings, Inc. (1.5%)
  • T&D Holdings, Inc. (1.4%)

Contact Details

  • Website:http://www.ono.co.jp
  • Address: 1-8-2 Kyutaromachi, Chuo-Ku, Osaka, 541-8564, Japan
  • Phone: +81.6.6263.5670

Related Companies

  • Ono Pharma Korea Co., Ltd.
  • Ono Pharma UK Ltd.
  • Ono Pharma USA, Inc.
  • Ono Shogakukai Foundation

Competitors

  • Agenus Inc.
  • Calithera Biosciences, Inc.
  • Cytokinetics, Incorporated
  • VistaGen Therapeutics, Inc.
  • BioLineRX Ltd.
Last Updated on 23 Apr, 2019

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends April 19th

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media